Juan Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Juan Li has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Chuanxin Wang
Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, China
57 shared publications - Peilong Li
Department of Clinical Laboratory, The Second Qilu Hospital of Shandong University, Jinan, China
54 shared publications - Qiuchen Qi
Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan 250033, PR China; Shandong Engineering & Technology Research Center for Tumor Marker Detection, Jinan 250033, PR China
50 shared publications - Jie Gao
Department of Clinical Laboratory, The Second Hospital of Shandong University, 247 Beiyuan Street, Jinan, 250033, Shandong, China
43 shared publications - Yunshan Wang
Department of Clinical Laboratory, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
43 shared publications - Maoxiao Feng
Department of Clinical Laboratory Shandong Provincial Hospital Affiliated to Shandong First Medical University Jinan Shandong China
42 shared publications
Latest Publications
- Open Access
- 16 June 2026
- Published by Wiley in Cancer Science
- Vol. 117 (10) , 2733-2751
Tumor‐Derived Exosomal piR ‐hsa‐28212 Promotes Lymphatic Metastasis in Breast Cancer
Lymph node (LN) metastasis is a critical indicator of poor prognosis in breast cancer (BC). BC‐derived exosomes influence intercellular communication within the tumor microenvironment, driving metastatic progression. However, the precise mechanisms by which exosomes facilitate LN metastasis in BC remain unclear. We performed small RNA sequencing on serum exosomes to identify Piwi‐interacting RNAs (piRNAs) associated with BC LN metastasis. Functional investigations of exosomal piR‐hsa‐28212 included in vitro assays for migration and tube formation of human lymphatic endothelial cells (HLECs), alongside an in vivo footpad‐popliteal LN metastasis model. Specific interactions between piR‐hsa‐28212 and TBX1 (T‐box transcription factor 1), as well as TBX1 and VEGF receptor 3 (VEGFR3), were validated through luciferase reporter assays. The stability of TBX1 mRNA was analyzed by actinomycin D assay. RNA pulldown, RNA immunoprecipitation (RIP), and RNA fluorescence in situ hybridization (FISH) assays were conducted to explore the interaction between piR‐hsa‐28212 and METTL3. PiR‐hsa‐28212 was significantly upregulated in serum exosomes of BC patients with LN metastasis. Exosomal piR‐hsa‐28212 enhanced HLECs migration and tube formation in vitro and promoted lymphangiogenesis and LN metastasis in vivo. Mechanistically, exosomal piR‐hsa‐28212 transferred from BC cells to HLECs stabilized TBX1 mRNA, thereby upregulating VEGFR3 expression. In BC cells, piR‐hsa‐28212 directly bound to and stabilized METTL3 protein, modulating N6‐methyladenosine (m6A) methylation of vascular endothelial growth factor C (VEGFC) mRNA and consequently increasing VEGFC expression and secretion. Collectively, these findings reveal an exosome‐mediated piRNA regulatory mechanism that synergistically amplifies VEGFC/VEGFR3 signaling to drive LN metastasis in BC, highlighting piR‐hsa‐28212 as a potential therapeutic target. Trial Registration: KYLL‐2022‐338
- 16 June 2026
- Published by Wiley in Cancer Science
- Vol. 117 (10) , 2733-2751
Open AccessTumor‐Derived Exosomal piR ‐hsa‐28212 Promotes Lymphatic Metastasis in Breast Cancer
Lymph node (LN) metastasis is a critical indicator of poor prognosis in breast cancer (BC). BC‐derived exosomes influence intercellular communication within the tumor microenvironment, driving metastatic progression. However, the precise mechanisms by which exosomes facilitate LN metastasis in BC remain unclear. We performed small RNA sequencing on serum exosomes to identify Piwi‐interacting RNAs (piRNAs) associated with BC LN metastasis. Functional investigations of exosomal piR‐hsa‐28212 included in vitro assays for migration and tube formation of human lymphatic endothelial cells (HLECs), alongside an in vivo footpad‐popliteal LN metastasis model. Specific interactions between piR‐hsa‐28212 and TBX1 (T‐box transcription factor 1), as well as TBX1 and VEGF receptor 3 (VEGFR3), were validated through luciferase reporter assays. The stability of TBX1 mRNA was analyzed by actinomycin D assay. RNA pulldown, RNA immunoprecipitation (RIP), and RNA fluorescence in situ hybridization (FISH) assays were conducted to explore the interaction between piR‐hsa‐28212 and METTL3. PiR‐hsa‐28212 was significantly upregulated in serum exosomes of BC patients with LN metastasis. Exosomal piR‐hsa‐28212 enhanced HLECs migration and tube formation in vitro and promoted lymphangiogenesis and LN metastasis in vivo. Mechanistically, exosomal piR‐hsa‐28212 transferred from BC cells to HLECs stabilized TBX1 mRNA, thereby upregulating VEGFR3 expression. In BC cells, piR‐hsa‐28212 directly bound to and stabilized METTL3 protein, modulating N6‐methyladenosine (m6A) methylation of vascular endothelial growth factor C (VEGFC) mRNA and consequently increasing VEGFC expression and secretion. Collectively, these findings reveal an exosome‐mediated piRNA regulatory mechanism that synergistically amplifies VEGFC/VEGFR3 signaling to drive LN metastasis in BC, highlighting piR‐hsa‐28212 as a potential therapeutic target. Trial Registration: KYLL‐2022‐338
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table2 from USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table2 from USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table1 from USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table1 from USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Original Image of western blot from USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer
Original Image of western blot
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessOriginal Image of western blot from USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer
Original Image of western blot
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
REAGENT or RESOURCE from USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessREAGENT or RESOURCE from USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table3 from USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table3 from USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures and Figure LegendsSupplementary Figures and Figure Legends from USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer
Supplementary figures and figure Legends
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures and Figure LegendsSupplementary Figures and Figure Legends from USP48 Stabilizes Gasdermin E to Promote Pyroptosis in Cancer
Supplementary figures and figure Legends
- 26 November 2025
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 33 (5) , 1004-1019
Ubiquitin-specific protease 48 drives malignant progression of colorectal cancer by suppressing autophagy through stabilizing sequestosome 1
Colorectal cancer (CRC) is the third malignant tumor in incidence rate and the second leading cause of cancer death worldwide. The progression of CRC is associated with both autophagy and ubiquitin-specific proteases (USPs). While USPs have been shown to regulate autophagy, their specific involvement in CRC autophagy remains largely unexplored. Herein, through the analysis of autophagy-related protein expression levels and proteomics, we found that high expression of USP48 was closely related to the inhibition of autophagy in CRC. And further analysis of CRC tissues showed that USP48 served as an independent risk factor for CRC patient prognosis. In vitro, we observed that USP48 significantly enhanced the proliferative, migration and invasion capacities of CRC cells. In vivo experiments showed that USP48 knockdown significantly inhibited the growth of subcutaneous tumors in nude mice, and the deletion of USP48 in intestinal epithelial cells reduced the number of intestinal tumors and mortality rate of mice. Mechanistically, USP48 was found to interact with the autophagy substrate protein sequestosome 1 (SQSTM1) and induce its deubiquitination at K420. This process inhibited autophagy, consequently maintaining the protein stability of SQSTM1. Rescue experiments demonstrated that SQSTM1 was the key target for USP48 to inhibit autophagy and promote CRC progression. Based on these findings, we constructed a tetrahedral DNA nanomaterial loaded with USP48 small interfering RNA (siRNA), which could effectively inhibited the progression of CRC in vivo while exhibiting excellent biocompatibility. In summary, our findings highlighted the role of USP48 in promoting CRC progression via the stabilization of SQSTM1, which leads to the suppression of autophagy. Thus, USP48 may be a potential therapeutic target for CRC.
- 26 November 2025
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 33 (5) , 1004-1019
Ubiquitin-specific protease 48 drives malignant progression of colorectal cancer by suppressing autophagy through stabilizing sequestosome 1
Colorectal cancer (CRC) is the third malignant tumor in incidence rate and the second leading cause of cancer death worldwide. The progression of CRC is associated with both autophagy and ubiquitin-specific proteases (USPs). While USPs have been shown to regulate autophagy, their specific involvement in CRC autophagy remains largely unexplored. Herein, through the analysis of autophagy-related protein expression levels and proteomics, we found that high expression of USP48 was closely related to the inhibition of autophagy in CRC. And further analysis of CRC tissues showed that USP48 served as an independent risk factor for CRC patient prognosis. In vitro, we observed that USP48 significantly enhanced the proliferative, migration and invasion capacities of CRC cells. In vivo experiments showed that USP48 knockdown significantly inhibited the growth of subcutaneous tumors in nude mice, and the deletion of USP48 in intestinal epithelial cells reduced the number of intestinal tumors and mortality rate of mice. Mechanistically, USP48 was found to interact with the autophagy substrate protein sequestosome 1 (SQSTM1) and induce its deubiquitination at K420. This process inhibited autophagy, consequently maintaining the protein stability of SQSTM1. Rescue experiments demonstrated that SQSTM1 was the key target for USP48 to inhibit autophagy and promote CRC progression. Based on these findings, we constructed a tetrahedral DNA nanomaterial loaded with USP48 small interfering RNA (siRNA), which could effectively inhibited the progression of CRC in vivo while exhibiting excellent biocompatibility. In summary, our findings highlighted the role of USP48 in promoting CRC progression via the stabilization of SQSTM1, which leads to the suppression of autophagy. Thus, USP48 may be a potential therapeutic target for CRC.